随着durvalumab维持治疗真实数据的增加，表明癌症宿主相互作用的免疫学标志可能会对未切除III期非小细胞肺癌患者多模式治疗的疗效产生重要影响。我们总结了关于这种新三模式方法的真实世界临床数据，并报告潜在的生物标记。在这种非常异质性的不可手术III期非小细胞肺癌疾病的情况下，显然的问题是：我们如何增强预测检查点抑制成功或失败的能力？哪些工具和生物标志物，哪些临床元数据和基因背景是相关和可行的？没有一个单一的生物标志物将完全主宰不能手术的III期非小细胞肺癌空间，因此我们倡导生物标志物的多级别和多元分析。在这篇特定的观点文章中，我们探讨了PD-L1表达在肿瘤细胞、中性粒细胞与淋巴细胞比值、EGFR和STK11突变状态、干扰素-γ标志、肿瘤浸润淋巴细胞等对肿瘤的影响。

The growing body of real-life data on maintenance treatment with durvalumab suggests that immunological markers of the cancer-host interplay may have significant effects on the efficacy of multimodal therapy in patients with unresectable stage III NSCLC.We summarize real-world clinical data regarding this new tri-modal approach and report on potential biomarker landscape.The obvious question posed in this context of a very heterogeneous inoperable stage III NSCLC disease is: How can we augment an ability to predict checkpoint inhibition success or failure? Which tools and biomarkers, which clinical metadata and genetic background are relevant and feasible? No single biomarker will ever fully dominate the unresectable stage III NSCLC space, so we advocate multilevel and multivariate analysis of biomarkers. In this particular opinion piece, we explore the impact of PD-L1 expression on tumor cells, neutrophil-to-lymphocyte ratio, EGFR and STK11 mutational status, interferon-gamma signature, and tumor-infiltrating lymphocytes among others.